DS
APRE icon

DRW Securities’s Aprea Therapeutics APRE Stock Holding History

DRW Securities’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-120,651
Closed -$103K – 1263
2025
Q4 		$103K Buy
+120,651
New +$148K ﹤0.01% 1065

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SRL
Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DRW Securities's APRE Position: Q1 2026 in Review

DRW Securities sold out of Aprea Therapeutics (APRE) in Q1 2026, closing a stake of 120,651 shares — an estimated $103K sold.

DRW Securities first reported a position in APRE in Q4 2025 and held it in 1 quarter. The position peaked at $103K in Q4 2025. 22 funds tracked by Wall St. Rank hold APRE as of Q1 2026.

  • DRW Securities reported no remaining Aprea Therapeutics position as of Q1 2026 after selling out during the quarter.
  • DRW Securities sold 120,651 Aprea Therapeutics shares in Q1 2026, an estimated $103K.
  • DRW Securities first reported a position in Aprea Therapeutics in Q4 2025 and held it in 1 quarter.
  • DRW Securities's Aprea Therapeutics position peaked at $103K in Q4 2025.
  • 22 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q1 2026.

Based on DRW Securities's 13F filing for Q1 2026, filed 13 May 2026.